Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · IEX Real-Time Price · USD
4.140
-0.120 (-2.82%)
Jul 22, 2024, 10:08 AM EDT - Market open
Monte Rosa Therapeutics Employees
Monte Rosa Therapeutics had 133 employees as of December 31, 2023. The number of employees increased by 10 or 8.13% compared to the previous year.
Employees
133
Change (1Y)
10
Growth (1Y)
8.13%
Revenue / Employee
$8,000
Profits / Employee
-$1,017,158
Market Cap
250.11M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 133 | 10 | 8.13% |
| Dec 31, 2022 | 123 | 30 | 32.26% |
| Dec 31, 2021 | 93 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Auna SA | 14,958 |
| MultiPlan | 2,800 |
| Viemed Healthcare | 996 |
| AirSculpt Technologies | 381 |
| Tenaya Therapeutics | 140 |
| Nektar Therapeutics | 137 |
| Zentalis Pharmaceuticals | 124 |
| Inovio Pharmaceuticals | 122 |
GLUE News
- 14 days ago - Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day - GlobeNewsWire
- 25 days ago - Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 - GlobeNewsWire
- 5 weeks ago - Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis - GlobeNewsWire
- 7 weeks ago - Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Monte Rosa Therapeutics Announces Leadership Team Promotions - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering - GlobeNewsWire
- 2 months ago - Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire